What is Celcuity's 2029?

Celcuity (CELC) reported 2029 of $44.01M in Q1 2026.

How has Celcuity's 2029 changed year-over-year?

Celcuity's 2029 decreased by 16.4% year-over-year, from $52.61M to $44.01M.

Over 4 years (2021 to 2025), Celcuity's 2029 has grown at a 66.3% compound annual growth rate (CAGR), from $5.74M to $43.9M.

BridgeBio PharmaBBIO

——

Operating income-$50.5M-39.8%

Net income-$52.8M-42.8%

EPS (diluted)-$0.97-12.8%

Cash & equivalents$145.2M+781%

Total debt$137.9M+30.7%

Total equity$53.5M-38.2%

Total assets$410.2M+88.0%

Operating cash flow-$55.1M-53.6%

CapEx$249.0K+315%

Free cash flow-$55.3M-54.0%

Market cap$4.4B+1,370%

Return on equity-275.2%-990pp

Debt / equity2.6×+1.4×

Current ratio12.3×+5.7×

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Celcuity's 2029?: Celcuity (CELC) reported 2029 of $44.01M in Q1 2026.
How has Celcuity's 2029 changed year-over-year?: Celcuity's 2029 decreased by 16.4% year-over-year, from $52.61M to $44.01M.
What is the long-term trend for Celcuity's 2029?: Over 4 years (2021 to 2025), Celcuity's 2029 has grown at a 66.3% compound annual growth rate (CAGR), from $5.74M to $43.9M.